Zymeworks Announces Participation in Upcoming Investor Conference

Rhea-AI Summary

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, will participate in the Jefferies Healthcare Conference on June 8-9. Management will hold one-on-one meetings and present on June 8 at 9:30 a.m. ET in New York, NY. The presentation will be available on Zymeworks’ website. Zymeworks focuses on next-generation multifunctional biotherapeutics, with lead candidate zanidatamab targeting HER2-positive solid tumors and ZW49 in Phase 1 development. For more details, visit their clinical trials page.

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:

• Jefferies Healthcare Conference. Zymeworks will participate in one-on-one meetings on June 8^th – 9^th and will present on June 8^th at 9:30 a.m. ET in New York, NY.

The presentation will be available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005050/en/

Investor Inquiries:

Jack Spinks

(604) 678-1388

ir@zymeworks.com

Media Inquiries:

Diana Papove

(604) 678-1388

media@zymeworks.com

Source: Zymeworks Inc.

FAQ

What is Zymeworks Inc. participating in on June 8-9?

Zymeworks Inc. is participating in the Jefferies Healthcare Conference, holding one-on-one meetings and presenting.

What time is Zymeworks' presentation at the Jefferies Healthcare Conference?

Zymeworks' presentation is scheduled for June 8 at 9:30 a.m. ET.

Where can I watch Zymeworks' presentation from the Jefferies Healthcare Conference?

The presentation will be available on Zymeworks’ website.

What are the lead clinical candidates of Zymeworks Inc.?

Zymeworks' lead clinical candidate is zanidatamab, targeting HER2-positive solid tumors, and ZW49 is in Phase 1 development.